SCM
RAPT

Superstring Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Superstring Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,449
Closed -$888K – 57
2025
Q3 		$888K Buy
34,449
+8,415
+32% +$110K 0.88% 30
2025
Q2 		$208K Buy
+26,034
New +$199K 0.25% 35

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Superstring Capital Management's RAPT Position: Q4 2025 in Review

Superstring Capital Management sold out of RAPT Therapeutics (RAPT) in Q4 2025, closing a stake of 34,449 shares — an estimated $888K sold.

Superstring Capital Management first reported a position in RAPT in Q2 2025 and held it in 2 quarters. The position peaked at $888K in Q3 2025. 105 funds tracked by Wall St. Rank hold RAPT as of Q4 2025.

  • Superstring Capital Management reported no remaining RAPT Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Superstring Capital Management sold 34,449 RAPT Therapeutics shares in Q4 2025, an estimated $888K.
  • Superstring Capital Management first reported a position in RAPT Therapeutics in Q2 2025 and held it in 2 quarters.
  • Superstring Capital Management's RAPT Therapeutics position peaked at $888K in Q3 2025.
  • 105 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2025.

Based on Superstring Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.